Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC28A3 regulatory antisense RNA 1 (SLC28A3-AS1)
- Target
- SLC28A3-AS1
- Molecular classification
- Other, Long non-coding RNA (lncRNA)
01
Overview
SLC28A3 regulatory antisense RNA 1 (SLC28A3-AS1) is a long non-coding RNA (lncRNA) gene that overlaps with the SLC28A3 coding region and regulates its expression[1][2][4]. SLC28A3-AS1 is not a protein, receptor, transporter, or enzyme, but a non-coding transcript involved in gene regulation. It has been implicated in mediating cardioprotective effects against anthracycline-induced cardiotoxicity, especially through the SNP rs11140490 which modulates its expression and subsequently reduces doxorubicin uptake in cardiomyocytes by repressing SLC28A3 transporter activity[2]. This lncRNA therefore represents a regulatory element relevant to pharmacogenomics and susceptibility to drug-induced heart toxicity, though it is not itself a direct pharmacological target[2][4].
- Other names
- SLC28A3-AS1
02
Mechanism of action
Regulation of transporter gene expression to modulate drug uptake
03
Biological functions
Regulation of SLC28A3 expressionModulation of drug-induced cardiotoxicity
04
Disease associations
Cardiovascular disease (anthracycline-induced cardiotoxicity)
05
Biomarkers
SNP rs11140490 at SLC28A3 locus (implicating SLC28A3-AS1 in cardioprotection)
Beyond the preview
Go deeper on SLC28A3 regulatory antisense RNA 1 (SLC28A3-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLC28A3 regulatory antisense RNA 1 (SLC28A3-AS1).